CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 345 enrolled
Drug / intervention
MEDI7352 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04675034
NCT04675034Phase 2Completed

A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee

AstraZeneca·interventional·Posted Dec 19, 2020·Updated Feb 10, 2025

In Brief

A Phase 2 clinical trial evaluating MEDI7352 and Placebo for Painful Osteoarthritis of the Knee. Completed, enrolled 345 participants across 41 sites in 6 countries.

Detailed Summary

This is a Phase IIb randomised, double-blind, placebo-controlled, dose-response study in participants with painful osteoarthritis (OA) of the knee. The study will assess the safety and efficacy of multiple doses of MEDI7352 compared to placebo, as well as the pharmacokinetics, pharmacodynamics and immunogenicity of MEDI7352 in participants with moderate to severe chronic pain persistent for 3 months or more not adequately controlled by standard of care treatments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Estonia, Germany, Poland, Spain, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 19, 2020
Enrollment StartDec 2, 2020
Primary CompletionAug 16, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.5 years ago

Interventions

MEDI7352drug

Participants will receive SC injection of MEDI7352 as stated in arm description.

Placeboother

Participants will receive SC injection of placebo as stated in arm description.